Novartis

NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

www.novartis.com

Novartis RSS Channel

Filters
List of articles in category Novartis
Title Published Date
Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors 05 September 2011
Novartis drug Afinitor® recommended by CHMP 25 July 2011
Novartis delivers strong financial results and four major approvals 19 July 2011
Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer 06 July 2011
Novartis drug Votubia® recommended by CHMP for approval in the EU 24 June 2011
Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 17 June 2011
Novartis gains European Commission approval for Lucentis® 07 June 2011
Novartis welcomes endorsement of Pandemic Influenza Preparedness Framework at World Health Assembly 25 May 2011
Novartis receives EU approval for Rasilamlo® 28 April 2011
Novartis makes strong start for the year 20 April 2011
Novartis receives European Commission approval for Gilenya® 21 March 2011
Novartis gains positive CHMP opinion for Rasilamlo(TM) 21 February 2011
Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET 09 February 2011
Innovation drives Novartis to double-digit growth for 2010 30 January 2011
Sandoz announces phase II clinical trial for biosimilar version of rituximab 13 January 2011
Novartis submits Bexsero® for regulatory review in Europe 02 January 2011
Commitment of Novartis in advancing treatments for patients with cancer and rare diseases 02 December 2010
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 18 November 2010
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate 04 November 2010
Novartis therapy Lucentis® recommended for approval in EU 25 October 2010
Build the future of health through collaboration & innovation